Bulletin
Investor Alert

June 30, 2022, 1:07 p.m. EDT

Liquid Biopsy Market Global Industry Growth Opportunities & Share Estimation 2029

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Biocept Inc. (BIOC)
  • X
    Qiagen N.V. (QGEN)
  • X
    Bio-Rad Laboratories Inc. Cl A (BIO)

or Cancel Already have a watchlist? Log In

Jun 30, 2022 (AmericaNewsHour) -- Research Nester published a report titled "Liquid Biopsy Market: Global Demand Analysis & Opportunity Outlook 2029" which delivers detailed overview of the global liquid biopsy market in terms of market segmentation by type of biomarker, application, sample collection type, product type, technology, end-user, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The global liquid biopsy market is segmented by end-user into academic & research centers, hospitals & laboratories, and others, out of which, the hospitals & laboratories segment is projected to hold the largest market share by the end of 2021 owing to the increasing number of tests being done in in-house hospital laboratories and external laboratories.

Get a PDF Sample for more detailed market insights: https://www.researchnester.com/sample-request-69

Increasing Prevalence of Cancer and the Need for Early Diagnosis

The World Health Organization (WHO), in one of its statistics, stated that globally, the second leading cause of death is cancer. Additionally, deaths caused due to cancer in the year 2018, registered to around 9.6 million cases.

The statistics portray the growing prevalence of cancer globally and therefore the increasing need amongst individuals for its early detection. Increasing preferences of medical practitioners for minimally invasive and non-invasive methods of sample collection for the detection of cancer is leading to the increase in adoption of liquid biopsy procedures. This procedure further allows the healthcare practitioners to gain more information on the cancer type and also allows real-time analysis. Moreover, increasing advancements in clinical research is further anticipated to drive the growth of the market during the forecast period.

The global liquid biopsy market is anticipated to grow with a significant CAGR during the forecast period, i.e., 2021-2029, owing to the numerous advantages of liquid biopsy over the conventional tumor biopsy, such as low risks, enhanced monitoring for drug response and resistance, and others, along with the rising awareness about minimally invasive procedures.

Regionally, the global liquid biopsy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa regions, out of which, the market in North America is anticipated to hold the largest market share by the end of 2021, backed by the growing healthcare infrastructure in the region, and the increasing advancements in research for the development of different analytical techniques for cancer.

However, the low specificity and sensitivity of liquid biopsy for the detection of cancer biomarkers is expected to operate as key restraint to the growth of the global liquid biopsy market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global liquid biopsy market which includes company profiling of OmeCare Inc. (Pathway Genomics), Biocept, Inc. /zigman2/quotes/206998585/composite BIOC +8.75% , Exosome Diagnostics, Inc., QIAGEN GmbH /zigman2/quotes/204869908/composite QGEN -0.15% , Roche Diagnostics (otcmkts:RHHBY), Bio-Rad Laboratories, Inc. /zigman2/quotes/207953537/composite BIO -0.47% , NeoGenomics Laboratories, Inc. /zigman2/quotes/202492506/composite NEO -5.98% , Biocartis NV (ebr:BCART), Guardant Health, Inc. /zigman2/quotes/201348336/composite GH +3.20% , and Trovagene, Inc. (Cardiff Oncology) /zigman2/quotes/201555650/composite CRDF +0.65% .

Access Full Report, here: https://www.researchnester.com/sample-request-69

The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global liquid biopsy market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Research Nester is a one-stop service provider, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives to make wise decisions for their future investment and expansion by providing them qualitative market insights and strategies while avoiding future uncertainties. We believe in honesty and sheer hard work that we trust is reflected in our work ethics. Our vision is not just limited to gain the trust of our clients but also to be equally respected by our employees and being appreciated by the competitors.

For more information, please contact:

AJ Daniel

Research Nester
Email: info@researchnester.com
Tel: +1-6465869123

The post Liquid Biopsy Market Global Industry Growth Opportunities & Share Estimation 2029 appeared first on America News Hour .

COMTEX_409485762/2606/2022-06-30T13:06:46

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

/zigman2/quotes/206998585/composite
US : U.S.: Nasdaq
$ 0.87
+0.07 +8.75%
Volume: 109,946
Sept. 27, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$13.54 million
Rev. per Employee
$330,405
loading...
/zigman2/quotes/204869908/composite
US : U.S.: NYSE
$ 40.90
-0.06 -0.15%
Volume: 830,505
Sept. 27, 2022 4:00p
P/E Ratio
18.37
Dividend Yield
N/A
Market Cap
$9.30 billion
Rev. per Employee
$375,091
loading...
/zigman2/quotes/207953537/composite
US : U.S.: NYSE
$ 412.59
-1.93 -0.47%
Volume: 116,911
Sept. 27, 2022 4:03p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$12.31 billion
Rev. per Employee
$363,415
loading...
/zigman2/quotes/202492506/composite
US : U.S.: Nasdaq
$ 8.34
-0.53 -5.98%
Volume: 935,573
Sept. 27, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.12 billion
Rev. per Employee
$244,656
loading...
/zigman2/quotes/201348336/composite
US : U.S.: Nasdaq
$ 49.59
+1.54 +3.20%
Volume: 678,190
Sept. 27, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$4.91 billion
Rev. per Employee
$297,254
loading...
/zigman2/quotes/201555650/composite
US : U.S.: Nasdaq
$ 1.55
+0.01 +0.65%
Volume: 334,872
Sept. 27, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$66.74 million
Rev. per Employee
$16,696
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.